Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Immunol. 2011 Feb 15;186(4):1887-90. doi: 10.4049/jimmunol.1090138.

Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.

Author information

  • 1Department of Neurology, The Ohio State University Medical Center, Columbus, OH 43210-1228, USA. michael.racke@osumc.edu

Abstract

Glatiramer acetate (GA) has been used as an immunomodulatory agent for the treatment of relapsing-remitting multiple sclerosis (MS) in the United States since 1996. It is currently one of two first-line agents for use in the treatment of relapsing-remitting MS. GA was the first agent to be used in the treatment of MS that was developed using the animal model of MS called experimental autoimmune encephalomyelitis. In this commentary, we examine the development of GA as a treatment for MS and discuss its mechanism of action as suggested by recent studies using modern immunologic methods.

PMID:
21289312
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk